Lot No: 1
II.2.1) Title
Lot 1 - North Lincolnshire and North East Lincolnshire
II.2.2) Additional CPV code(s)
85140000
II.2.3) Place of performance
NUTS code:
UKE13
Main site or place of performance:
Lot 1 - North Lincolnshire and North East Lincolnshire
II.2.4) Description of the procurement
NHS England - North East and Yorkshire (the Relevant Authority) intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Following the government's acceptance of the Joint Committee on Vaccination and Immunisation (JCVI) advice that the NHS should implement:
• a routine mpox pre-exposure vaccination programme building on the existing offer JCVI statement on mpox vaccination as a routine programme - GOV.UK
• a routine opportunistic gonorrhoea vaccination programme JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK
The Relevant Authority is now seeking suitable providers by no later than 01 September 2025 necsu.psrprocurement@nhs.net to deliver the vaccinations alongside existing vaccination programmes (HPV GBMSM) delivered in place-based Local Authority commissioned sexual health services. Providers must deliver sexual health services in identified localities and work with partners to ensure effective programme coverage and equity of access to the local eligible population.
Eligibility
The JCVI advised that the vaccination programmes, which have similar eligibility criteria, should primarily target gay, bisexual and other men who have sex with men (GBMSM) who meet the eligibility criteria and are at highest risk of exposure to Mpox and Gonorrhoea. There may also be a small number of individuals other than GBMSM with a similar risk of infection as the eligible GBMSM groups who can be offered the vaccines.
Individuals should be identified through sexual health services using markers of high risk of infection. This includes a recent history of multiple sexual partners or recent bacterial sexually transmitted infection. Full details on the eligible cohorts for each programme are available in the service specifications for each programme.
Activity/funding
Funding of £10.06 will be provided for each dose of vaccine delivered to members of the identified cohort. An additional £8.00 per vaccination delivered will be provided in 2025/26 to support mobilisation. This additional implementation payment will be reviewed in advance of 2026/27 contract year.
As these are newly developed programmes, no baseline activity level for these vaccinations is available. Activity delivered in 2025/26 will be used to determine an Indicative Activity Plan for 2026/27 and future contract years.
Delivery date
Providers should build on the existing delivery of vaccinations including HPV GBMSM and the accelerated Mpox vaccination programme (where implemented) and make arrangements to deliver to the eligible population accessing their services from August 2025. Providers should be offering both vaccines by no later than 01 September 2025.
Provider Eligibility Criteria:
Eligible providers must:
• Hold a current Local Authority contract for the delivery of Sexual Health Services for one or more of the Lots/Localities as identified in this procurement process.
• Pass all questions within the Regulation 20 questionnaire parts 1 and part 2 and the associated quality and financial stability assessment in part 3 of the questionnaire.
Contract Term:
To commence in August 2025 and providers should be offering both vaccines by no later than 01 September 2025. The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Location/Lot:
Yorkshire & Humber:
• Lot 1 - North Lincolnshire and North East Lincolnshire - service to commence by 01 September with an expiry 31 March 2029 - with option to extend for 2-years (1+1).
II.2.5) Award criteria
Quality criterion: Patient Choice
/ Weighting: 100
Cost criterion: Patient Choice
/ Weighting: 100
II.2.11) Information about options
Options:
Yes
Description of options:
The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority: Lot 1 - North Lincolnshire and North East Lincolnshire - service to commence by 01 September with an expiry 31 March 2029 - with option to extend for 2-years (1+1).
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
Lot 2 - Hull
II.2.2) Additional CPV code(s)
85140000
II.2.3) Place of performance
NUTS code:
UKE11
Main site or place of performance:
Lot 2 - Hull
II.2.4) Description of the procurement
NHS England - North East and Yorkshire (the Relevant Authority) intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Following the government's acceptance of the Joint Committee on Vaccination and Immunisation (JCVI) advice that the NHS should implement:
• a routine mpox pre-exposure vaccination programme building on the existing offer JCVI statement on mpox vaccination as a routine programme - GOV.UK
• a routine opportunistic gonorrhoea vaccination programme JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK
The Relevant Authority is now seeking suitable providers by no later than 01 September 2025 necsu.psrprocurement@nhs.net to deliver the vaccinations alongside existing vaccination programmes (HPV GBMSM) delivered in place-based Local Authority commissioned sexual health services. Providers must deliver sexual health services in identified localities and work with partners to ensure effective programme coverage and equity of access to the local eligible population.
Eligibility
The JCVI advised that the vaccination programmes, which have similar eligibility criteria, should primarily target gay, bisexual and other men who have sex with men (GBMSM) who meet the eligibility criteria and are at highest risk of exposure to Mpox and Gonorrhoea. There may also be a small number of individuals other than GBMSM with a similar risk of infection as the eligible GBMSM groups who can be offered the vaccines.
Individuals should be identified through sexual health services using markers of high risk of infection. This includes a recent history of multiple sexual partners or recent bacterial sexually transmitted infection. Full details on the eligible cohorts for each programme are available in the service specifications for each programme.
Activity/funding
Funding of £10.06 will be provided for each dose of vaccine delivered to members of the identified cohort. An additional £8.00 per vaccination delivered will be provided in 2025/26 to support mobilisation. This additional implementation payment will be reviewed in advance of 2026/27 contract year.
As these are newly developed programmes, no baseline activity level for these vaccinations is available. Activity delivered in 2025/26 will be used to determine an Indicative Activity Plan for 2026/27 and future contract years.
Delivery date
Providers should build on the existing delivery of vaccinations including HPV GBMSM and the accelerated Mpox vaccination programme (where implemented) and make arrangements to deliver to the eligible population accessing their services from August 2025. Providers should be offering both vaccines by no later than 01 September 2025.
Provider Eligibility Criteria:
Eligible providers must:
• Hold a current Local Authority contract for the delivery of Sexual Health Services for one or more of the Lots/Localities as identified in this procurement process.
• Pass all questions within the Regulation 20 questionnaire parts 1 and part 2 and the associated quality and financial stability assessment in part 3 of the questionnaire.
Contract Term:
To commence in August 2025 and providers should be offering both vaccines by no later than 01 September 2025. The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Location/Lot:
Yorkshire & Humber:
• Lot 2 - Hull - service to commence by 01 September with an expiry 01 April 2026 with option to extend for 6-years (4+2).
II.2.5) Award criteria
Quality criterion: Patient Choice
/ Weighting: 100
Cost criterion: Patient Choice
/ Weighting: 100
II.2.11) Information about options
Options:
Yes
Description of options:
The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority: • Lot 2 - Hull - service to commence by 01 September with an expiry 01 April 2026 with option to extend for 6-years (4+2).
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
Lot 3 - East Riding
II.2.2) Additional CPV code(s)
85140000
II.2.3) Place of performance
NUTS code:
UKE12
Main site or place of performance:
Lot 3 - East Riding
II.2.4) Description of the procurement
NHS England - North East and Yorkshire (the Relevant Authority) intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Following the government's acceptance of the Joint Committee on Vaccination and Immunisation (JCVI) advice that the NHS should implement:
• a routine mpox pre-exposure vaccination programme building on the existing offer JCVI statement on mpox vaccination as a routine programme - GOV.UK
• a routine opportunistic gonorrhoea vaccination programme JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK
The Relevant Authority is now seeking suitable providers by no later than 01 September 2025 necsu.psrprocurement@nhs.net to deliver the vaccinations alongside existing vaccination programmes (HPV GBMSM) delivered in place-based Local Authority commissioned sexual health services. Providers must deliver sexual health services in identified localities and work with partners to ensure effective programme coverage and equity of access to the local eligible population.
Eligibility
The JCVI advised that the vaccination programmes, which have similar eligibility criteria, should primarily target gay, bisexual and other men who have sex with men (GBMSM) who meet the eligibility criteria and are at highest risk of exposure to Mpox and Gonorrhoea. There may also be a small number of individuals other than GBMSM with a similar risk of infection as the eligible GBMSM groups who can be offered the vaccines.
Individuals should be identified through sexual health services using markers of high risk of infection. This includes a recent history of multiple sexual partners or recent bacterial sexually transmitted infection. Full details on the eligible cohorts for each programme are available in the service specifications for each programme.
Activity/funding
Funding of £10.06 will be provided for each dose of vaccine delivered to members of the identified cohort. An additional £8.00 per vaccination delivered will be provided in 2025/26 to support mobilisation. This additional implementation payment will be reviewed in advance of 2026/27 contract year.
As these are newly developed programmes, no baseline activity level for these vaccinations is available. Activity delivered in 2025/26 will be used to determine an Indicative Activity Plan for 2026/27 and future contract years.
Delivery date
Providers should build on the existing delivery of vaccinations including HPV GBMSM and the accelerated Mpox vaccination programme (where implemented) and make arrangements to deliver to the eligible population accessing their services from August 2025. Providers should be offering both vaccines by no later than 01 September 2025.
Provider Eligibility Criteria:
Eligible providers must:
• Hold a current Local Authority contract for the delivery of Sexual Health Services for one or more of the Lots/Localities as identified in this procurement process.
• Pass all questions within the Regulation 20 questionnaire parts 1 and part 2 and the associated quality and financial stability assessment in part 3 of the questionnaire.
Contract Term:
To commence in August 2025 and providers should be offering both vaccines by no later than 01 September 2025. The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Location/Lot:
Yorkshire & Humber:
Lot 3 - East Riding - service to commence by 01 September with an expiry 31 March 2026.
II.2.5) Award criteria
Quality criterion: Patient Choice
/ Weighting: 100
Cost criterion: Patient Choice
/ Weighting: 100
II.2.11) Information about options
Options:
Yes
Description of options:
The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority: Lot 3 - East Riding - service to commence by 01 September with an expiry 31 March 2026.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 4
II.2.1) Title
Lot 4 - Leeds
II.2.2) Additional CPV code(s)
85140000
II.2.3) Place of performance
NUTS code:
UKE42
Main site or place of performance:
Lot 4 - Leeds
II.2.4) Description of the procurement
NHS England - North East and Yorkshire (the Relevant Authority) intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Following the government's acceptance of the Joint Committee on Vaccination and Immunisation (JCVI) advice that the NHS should implement:
• a routine mpox pre-exposure vaccination programme building on the existing offer JCVI statement on mpox vaccination as a routine programme - GOV.UK
• a routine opportunistic gonorrhoea vaccination programme JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK
The Relevant Authority is now seeking suitable providers by no later than 01 September 2025 necsu.psrprocurement@nhs.net to deliver the vaccinations alongside existing vaccination programmes (HPV GBMSM) delivered in place-based Local Authority commissioned sexual health services. Providers must deliver sexual health services in identified localities and work with partners to ensure effective programme coverage and equity of access to the local eligible population.
Eligibility
The JCVI advised that the vaccination programmes, which have similar eligibility criteria, should primarily target gay, bisexual and other men who have sex with men (GBMSM) who meet the eligibility criteria and are at highest risk of exposure to Mpox and Gonorrhoea. There may also be a small number of individuals other than GBMSM with a similar risk of infection as the eligible GBMSM groups who can be offered the vaccines.
Individuals should be identified through sexual health services using markers of high risk of infection. This includes a recent history of multiple sexual partners or recent bacterial sexually transmitted infection. Full details on the eligible cohorts for each programme are available in the service specifications for each programme.
Activity/funding
Funding of £10.06 will be provided for each dose of vaccine delivered to members of the identified cohort. An additional £8.00 per vaccination delivered will be provided in 2025/26 to support mobilisation. This additional implementation payment will be reviewed in advance of 2026/27 contract year.
As these are newly developed programmes, no baseline activity level for these vaccinations is available. Activity delivered in 2025/26 will be used to determine an Indicative Activity Plan for 2026/27 and future contract years.
Delivery date
Providers should build on the existing delivery of vaccinations including HPV GBMSM and the accelerated Mpox vaccination programme (where implemented) and make arrangements to deliver to the eligible population accessing their services from August 2025. Providers should be offering both vaccines by no later than 01 September 2025.
Provider Eligibility Criteria:
Eligible providers must:
• Hold a current Local Authority contract for the delivery of Sexual Health Services for one or more of the Lots/Localities as identified in this procurement process.
• Pass all questions within the Regulation 20 questionnaire parts 1 and part 2 and the associated quality and financial stability assessment in part 3 of the questionnaire.
Contract Term:
To commence in August 2025 and providers should be offering both vaccines by no later than 01 September 2025. The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Location/Lot:
Yorkshire & Humber:
• Lot 4 - Leeds - service to commence by 01 September with an expiry 31 March 2030 with option to extend by 4-years.
II.2.5) Award criteria
Quality criterion: Patient Choice
/ Weighting: 100
Cost criterion: Patient Choice
/ Weighting: 100
II.2.11) Information about options
Options:
Yes
Description of options:
The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority: Lot 4 - Leeds - service to commence by 01 September with an expiry 31 March 2030 with option to extend by 4-years.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 5
II.2.1) Title
Lot 5 - Bradford
II.2.2) Additional CPV code(s)
85140000
II.2.3) Place of performance
NUTS code:
UKE41
Main site or place of performance:
Lot 5 - Bradford
II.2.4) Description of the procurement
NHS England - North East and Yorkshire (the Relevant Authority) intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Following the government's acceptance of the Joint Committee on Vaccination and Immunisation (JCVI) advice that the NHS should implement:
• a routine mpox pre-exposure vaccination programme building on the existing offer JCVI statement on mpox vaccination as a routine programme - GOV.UK
• a routine opportunistic gonorrhoea vaccination programme JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK
The Relevant Authority is now seeking suitable providers by no later than 01 September 2025 necsu.psrprocurement@nhs.net to deliver the vaccinations alongside existing vaccination programmes (HPV GBMSM) delivered in place-based Local Authority commissioned sexual health services. Providers must deliver sexual health services in identified localities and work with partners to ensure effective programme coverage and equity of access to the local eligible population.
Eligibility
The JCVI advised that the vaccination programmes, which have similar eligibility criteria, should primarily target gay, bisexual and other men who have sex with men (GBMSM) who meet the eligibility criteria and are at highest risk of exposure to Mpox and Gonorrhoea. There may also be a small number of individuals other than GBMSM with a similar risk of infection as the eligible GBMSM groups who can be offered the vaccines.
Individuals should be identified through sexual health services using markers of high risk of infection. This includes a recent history of multiple sexual partners or recent bacterial sexually transmitted infection. Full details on the eligible cohorts for each programme are available in the service specifications for each programme.
Activity/funding
Funding of £10.06 will be provided for each dose of vaccine delivered to members of the identified cohort. An additional £8.00 per vaccination delivered will be provided in 2025/26 to support mobilisation. This additional implementation payment will be reviewed in advance of 2026/27 contract year.
As these are newly developed programmes, no baseline activity level for these vaccinations is available. Activity delivered in 2025/26 will be used to determine an Indicative Activity Plan for 2026/27 and future contract years.
Delivery date
Providers should build on the existing delivery of vaccinations including HPV GBMSM and the accelerated Mpox vaccination programme (where implemented) and make arrangements to deliver to the eligible population accessing their services from August 2025. Providers should be offering both vaccines by no later than 01 September 2025.
Provider Eligibility Criteria:
Eligible providers must:
• Hold a current Local Authority contract for the delivery of Sexual Health Services for one or more of the Lots/Localities as identified in this procurement process.
• Pass all questions within the Regulation 20 questionnaire parts 1 and part 2 and the associated quality and financial stability assessment in part 3 of the questionnaire.
Contract Term:
To commence in August 2025 and providers should be offering both vaccines by no later than 01 September 2025. The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Location/Lot:
Yorkshire & Humber:
• Lot 5 - Bradford - service to commence by 01 September with an expiry 31 March 2033.
II.2.5) Award criteria
Quality criterion: Patient Choice
/ Weighting: 100
Cost criterion: Patient Choice
/ Weighting: 100
II.2.11) Information about options
Options:
Yes
Description of options:
The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority: Lot 5 - Bradford - service to commence by 01 September with an expiry 31 March 2033.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 6
II.2.1) Title
Lot 6 - Kirklees
II.2.2) Additional CPV code(s)
85140000
II.2.3) Place of performance
NUTS code:
UKE4
Main site or place of performance:
Lot 6 - Kirklees
II.2.4) Description of the procurement
NHS England - North East and Yorkshire (the Relevant Authority) intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Following the government's acceptance of the Joint Committee on Vaccination and Immunisation (JCVI) advice that the NHS should implement:
• a routine mpox pre-exposure vaccination programme building on the existing offer JCVI statement on mpox vaccination as a routine programme - GOV.UK
• a routine opportunistic gonorrhoea vaccination programme JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK
The Relevant Authority is now seeking suitable providers by no later than 01 September 2025 necsu.psrprocurement@nhs.net to deliver the vaccinations alongside existing vaccination programmes (HPV GBMSM) delivered in place-based Local Authority commissioned sexual health services. Providers must deliver sexual health services in identified localities and work with partners to ensure effective programme coverage and equity of access to the local eligible population.
Eligibility
The JCVI advised that the vaccination programmes, which have similar eligibility criteria, should primarily target gay, bisexual and other men who have sex with men (GBMSM) who meet the eligibility criteria and are at highest risk of exposure to Mpox and Gonorrhoea. There may also be a small number of individuals other than GBMSM with a similar risk of infection as the eligible GBMSM groups who can be offered the vaccines.
Individuals should be identified through sexual health services using markers of high risk of infection. This includes a recent history of multiple sexual partners or recent bacterial sexually transmitted infection. Full details on the eligible cohorts for each programme are available in the service specifications for each programme.
Activity/funding
Funding of £10.06 will be provided for each dose of vaccine delivered to members of the identified cohort. An additional £8.00 per vaccination delivered will be provided in 2025/26 to support mobilisation. This additional implementation payment will be reviewed in advance of 2026/27 contract year.
As these are newly developed programmes, no baseline activity level for these vaccinations is available. Activity delivered in 2025/26 will be used to determine an Indicative Activity Plan for 2026/27 and future contract years.
Delivery date
Providers should build on the existing delivery of vaccinations including HPV GBMSM and the accelerated Mpox vaccination programme (where implemented) and make arrangements to deliver to the eligible population accessing their services from August 2025. Providers should be offering both vaccines by no later than 01 September 2025.
Provider Eligibility Criteria:
Eligible providers must:
• Hold a current Local Authority contract for the delivery of Sexual Health Services for one or more of the Lots/Localities as identified in this procurement process.
• Pass all questions within the Regulation 20 questionnaire parts 1 and part 2 and the associated quality and financial stability assessment in part 3 of the questionnaire.
Contract Term:
To commence in August 2025 and providers should be offering both vaccines by no later than 01 September 2025. The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Location/Lot:
Yorkshire & Humber:
• Lot 6 - Kirklees - service to commence by 01 September with an expiry 31 March 2032.
II.2.5) Award criteria
Quality criterion: Patient Choice
/ Weighting: 100
Cost criterion: Patient Choice
/ Weighting: 100
II.2.11) Information about options
Options:
Yes
Description of options:
The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority: Lot 6 - Kirklees - service to commence by 01 September with an expiry 31 March 2032.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 7
II.2.1) Title
Lot 7 - Wakefield
II.2.2) Additional CPV code(s)
85140000
II.2.3) Place of performance
NUTS code:
UKE45
Main site or place of performance:
Lot 7 - Wakefield
II.2.4) Description of the procurement
NHS England - North East and Yorkshire (the Relevant Authority) intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Following the government's acceptance of the Joint Committee on Vaccination and Immunisation (JCVI) advice that the NHS should implement:
• a routine mpox pre-exposure vaccination programme building on the existing offer JCVI statement on mpox vaccination as a routine programme - GOV.UK
• a routine opportunistic gonorrhoea vaccination programme JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK
The Relevant Authority is now seeking suitable providers by no later than 01 September 2025 necsu.psrprocurement@nhs.net to deliver the vaccinations alongside existing vaccination programmes (HPV GBMSM) delivered in place-based Local Authority commissioned sexual health services. Providers must deliver sexual health services in identified localities and work with partners to ensure effective programme coverage and equity of access to the local eligible population.
Eligibility
The JCVI advised that the vaccination programmes, which have similar eligibility criteria, should primarily target gay, bisexual and other men who have sex with men (GBMSM) who meet the eligibility criteria and are at highest risk of exposure to Mpox and Gonorrhoea. There may also be a small number of individuals other than GBMSM with a similar risk of infection as the eligible GBMSM groups who can be offered the vaccines.
Individuals should be identified through sexual health services using markers of high risk of infection. This includes a recent history of multiple sexual partners or recent bacterial sexually transmitted infection. Full details on the eligible cohorts for each programme are available in the service specifications for each programme.
Activity/funding
Funding of £10.06 will be provided for each dose of vaccine delivered to members of the identified cohort. An additional £8.00 per vaccination delivered will be provided in 2025/26 to support mobilisation. This additional implementation payment will be reviewed in advance of 2026/27 contract year.
As these are newly developed programmes, no baseline activity level for these vaccinations is available. Activity delivered in 2025/26 will be used to determine an Indicative Activity Plan for 2026/27 and future contract years.
Delivery date
Providers should build on the existing delivery of vaccinations including HPV GBMSM and the accelerated Mpox vaccination programme (where implemented) and make arrangements to deliver to the eligible population accessing their services from August 2025. Providers should be offering both vaccines by no later than 01 September 2025.
Provider Eligibility Criteria:
Eligible providers must:
• Hold a current Local Authority contract for the delivery of Sexual Health Services for one or more of the Lots/Localities as identified in this procurement process.
• Pass all questions within the Regulation 20 questionnaire parts 1 and part 2 and the associated quality and financial stability assessment in part 3 of the questionnaire.
Contract Term:
To commence in August 2025 and providers should be offering both vaccines by no later than 01 September 2025. The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Location/Lot:
Yorkshire & Humber:
• Lot 7 - Wakefield - service to commence by 01 September with an expiry 30 September 2031.
II.2.5) Award criteria
Quality criterion: Patient Choice
/ Weighting: 100
Cost criterion: Patient Choice
/ Weighting: 100
II.2.11) Information about options
Options:
Yes
Description of options:
The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Lot 7 - Wakefield - service to commence by 01 September with an expiry 30 September 2031.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 8
II.2.1) Title
Lot 8 - Barnsley
II.2.2) Additional CPV code(s)
85140000
II.2.3) Place of performance
NUTS code:
UKE31
Main site or place of performance:
Lot 8 - Barnsley
II.2.4) Description of the procurement
NHS England - North East and Yorkshire (the Relevant Authority) intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Following the government's acceptance of the Joint Committee on Vaccination and Immunisation (JCVI) advice that the NHS should implement:
• a routine mpox pre-exposure vaccination programme building on the existing offer JCVI statement on mpox vaccination as a routine programme - GOV.UK
• a routine opportunistic gonorrhoea vaccination programme JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK
The Relevant Authority is now seeking suitable providers by no later than 01 September 2025 necsu.psrprocurement@nhs.net to deliver the vaccinations alongside existing vaccination programmes (HPV GBMSM) delivered in place-based Local Authority commissioned sexual health services. Providers must deliver sexual health services in identified localities and work with partners to ensure effective programme coverage and equity of access to the local eligible population.
Eligibility
The JCVI advised that the vaccination programmes, which have similar eligibility criteria, should primarily target gay, bisexual and other men who have sex with men (GBMSM) who meet the eligibility criteria and are at highest risk of exposure to Mpox and Gonorrhoea. There may also be a small number of individuals other than GBMSM with a similar risk of infection as the eligible GBMSM groups who can be offered the vaccines.
Individuals should be identified through sexual health services using markers of high risk of infection. This includes a recent history of multiple sexual partners or recent bacterial sexually transmitted infection. Full details on the eligible cohorts for each programme are available in the service specifications for each programme.
Activity/funding
Funding of £10.06 will be provided for each dose of vaccine delivered to members of the identified cohort. An additional £8.00 per vaccination delivered will be provided in 2025/26 to support mobilisation. This additional implementation payment will be reviewed in advance of 2026/27 contract year.
As these are newly developed programmes, no baseline activity level for these vaccinations is available. Activity delivered in 2025/26 will be used to determine an Indicative Activity Plan for 2026/27 and future contract years.
Delivery date
Providers should build on the existing delivery of vaccinations including HPV GBMSM and the accelerated Mpox vaccination programme (where implemented) and make arrangements to deliver to the eligible population accessing their services from August 2025. Providers should be offering both vaccines by no later than 01 September 2025.
Provider Eligibility Criteria:
Eligible providers must:
• Hold a current Local Authority contract for the delivery of Sexual Health Services for one or more of the Lots/Localities as identified in this procurement process.
• Pass all questions within the Regulation 20 questionnaire parts 1 and part 2 and the associated quality and financial stability assessment in part 3 of the questionnaire.
Contract Term:
To commence in August 2025 and providers should be offering both vaccines by no later than 01 September 2025. The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Location/Lot:
Yorkshire & Humber:
• Lot 8 - Barnsley - service to commence by 01 September with an expiry 30 June 2028.
II.2.5) Award criteria
Quality criterion: Patient Choice
/ Weighting: 100
Cost criterion: Patient Choice
/ Weighting: 100
II.2.11) Information about options
Options:
Yes
Description of options:
The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Lot 8 - Barnsley - service to commence by 01 September with an expiry 30 June 2028.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 9
II.2.1) Title
Lot 9 - Doncaster
II.2.2) Additional CPV code(s)
85140000
II.2.3) Place of performance
NUTS code:
UKE31
Main site or place of performance:
Lot 9 - Doncaster
II.2.4) Description of the procurement
NHS England - North East and Yorkshire (the Relevant Authority) intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Following the government's acceptance of the Joint Committee on Vaccination and Immunisation (JCVI) advice that the NHS should implement:
• a routine mpox pre-exposure vaccination programme building on the existing offer JCVI statement on mpox vaccination as a routine programme - GOV.UK
• a routine opportunistic gonorrhoea vaccination programme JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK
The Relevant Authority is now seeking suitable providers by no later than 01 September 2025 necsu.psrprocurement@nhs.net to deliver the vaccinations alongside existing vaccination programmes (HPV GBMSM) delivered in place-based Local Authority commissioned sexual health services. Providers must deliver sexual health services in identified localities and work with partners to ensure effective programme coverage and equity of access to the local eligible population.
Eligibility
The JCVI advised that the vaccination programmes, which have similar eligibility criteria, should primarily target gay, bisexual and other men who have sex with men (GBMSM) who meet the eligibility criteria and are at highest risk of exposure to Mpox and Gonorrhoea. There may also be a small number of individuals other than GBMSM with a similar risk of infection as the eligible GBMSM groups who can be offered the vaccines.
Individuals should be identified through sexual health services using markers of high risk of infection. This includes a recent history of multiple sexual partners or recent bacterial sexually transmitted infection. Full details on the eligible cohorts for each programme are available in the service specifications for each programme.
Activity/funding
Funding of £10.06 will be provided for each dose of vaccine delivered to members of the identified cohort. An additional £8.00 per vaccination delivered will be provided in 2025/26 to support mobilisation. This additional implementation payment will be reviewed in advance of 2026/27 contract year.
As these are newly developed programmes, no baseline activity level for these vaccinations is available. Activity delivered in 2025/26 will be used to determine an Indicative Activity Plan for 2026/27 and future contract years.
Delivery date
Providers should build on the existing delivery of vaccinations including HPV GBMSM and the accelerated Mpox vaccination programme (where implemented) and make arrangements to deliver to the eligible population accessing their services from August 2025. Providers should be offering both vaccines by no later than 01 September 2025.
Provider Eligibility Criteria:
Eligible providers must:
• Hold a current Local Authority contract for the delivery of Sexual Health Services for one or more of the Lots/Localities as identified in this procurement process.
• Pass all questions within the Regulation 20 questionnaire parts 1 and part 2 and the associated quality and financial stability assessment in part 3 of the questionnaire.
Contract Term:
To commence in August 2025 and providers should be offering both vaccines by no later than 01 September 2025. The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Location/Lot:
Yorkshire & Humber:
• Lot 9 - Doncaster - service to commence by 01 September with an expiry 30 September 2027.
II.2.5) Award criteria
Quality criterion: Patient Choice
/ Weighting: 100
Cost criterion: Patient Choice
/ Weighting: 100
II.2.11) Information about options
Options:
Yes
Description of options:
The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Lot 9 - Doncaster - service to commence by 01 September with an expiry 30 September 2027.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 10
II.2.1) Title
Lot 10 - Newcastle Upon Tyne
II.2.2) Additional CPV code(s)
85140000
II.2.3) Place of performance
NUTS code:
UKC22
Main site or place of performance:
Lot 10 - Newcastle Upon Tyne
II.2.4) Description of the procurement
NHS England - North East and Yorkshire (the Relevant Authority) intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Following the government's acceptance of the Joint Committee on Vaccination and Immunisation (JCVI) advice that the NHS should implement:
• a routine mpox pre-exposure vaccination programme building on the existing offer JCVI statement on mpox vaccination as a routine programme - GOV.UK
• a routine opportunistic gonorrhoea vaccination programme JCVI advice on the use of meningococcal B vaccination for the prevention of gonorrhoea - GOV.UK
The Relevant Authority is now seeking suitable providers by no later than 01 September 2025 necsu.psrprocurement@nhs.net to deliver the vaccinations alongside existing vaccination programmes (HPV GBMSM) delivered in place-based Local Authority commissioned sexual health services. Providers must deliver sexual health services in identified localities and work with partners to ensure effective programme coverage and equity of access to the local eligible population.
Eligibility
The JCVI advised that the vaccination programmes, which have similar eligibility criteria, should primarily target gay, bisexual and other men who have sex with men (GBMSM) who meet the eligibility criteria and are at highest risk of exposure to Mpox and Gonorrhoea. There may also be a small number of individuals other than GBMSM with a similar risk of infection as the eligible GBMSM groups who can be offered the vaccines.
Individuals should be identified through sexual health services using markers of high risk of infection. This includes a recent history of multiple sexual partners or recent bacterial sexually transmitted infection. Full details on the eligible cohorts for each programme are available in the service specifications for each programme.
Activity/funding
Funding of £10.06 will be provided for each dose of vaccine delivered to members of the identified cohort. An additional £8.00 per vaccination delivered will be provided in 2025/26 to support mobilisation. This additional implementation payment will be reviewed in advance of 2026/27 contract year.
As these are newly developed programmes, no baseline activity level for these vaccinations is available. Activity delivered in 2025/26 will be used to determine an Indicative Activity Plan for 2026/27 and future contract years.
Delivery date
Providers should build on the existing delivery of vaccinations including HPV GBMSM and the accelerated Mpox vaccination programme (where implemented) and make arrangements to deliver to the eligible population accessing their services from August 2025. Providers should be offering both vaccines by no later than 01 September 2025.
Provider Eligibility Criteria:
Eligible providers must:
• Hold a current Local Authority contract for the delivery of Sexual Health Services for one or more of the Lots/Localities as identified in this procurement process.
• Pass all questions within the Regulation 20 questionnaire parts 1 and part 2 and the associated quality and financial stability assessment in part 3 of the questionnaire.
Contract Term:
To commence in August 2025 and providers should be offering both vaccines by no later than 01 September 2025. The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Location/Lot:
North East and North Cumbria:
• Lot 10 - Newcastle Upon Tyne - service to commence by 01 September expiry 30 September 2030.
II.2.5) Award criteria
Quality criterion: Patient Choice
/ Weighting: 100
Cost criterion: Patient Choice
/ Weighting: 100
II.2.11) Information about options
Options:
Yes
Description of options:
The contract term will be co-terminus with the Local Authority contract for Sexual Health Services as highlighted for each Location/Lot which includes any permissible extension periods which would be subject to the enactment of the Local Authority:
Lot 10 - Newcastle Upon Tyne - service to commence by 01 September expiry 30 September 2030.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
The contract has been awarded to a group of economic operators:
No
The contract has been awarded to a group of economic operators:
No
The contract has been awarded to a group of economic operators:
No
The contract has been awarded to a group of economic operators:
No
The contract has been awarded to a group of economic operators:
No
The contract has been awarded to a group of economic operators:
No
The contract has been awarded to a group of economic operators:
No
The contract has been awarded to a group of economic operators:
No
The contract has been awarded to a group of economic operators:
No
The contract has been awarded to a group of economic operators:
No
The Relevant Authority intends to award these contracts under the Direct Award Process B under the Health Care Services (Provider Selection Regime) Regulations 2023.
All new services - All existing providers.
For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to these awards.
Deputy Head of Public Health, Yorkshire and the Humber, NHS England (North East and Yorkshire).
Senior Commissioning Manager - North East and North Cumbria, NHS England (North East and Yorkshire).
Screening and Immunisation Place Lead North Lincolnshire and North East Lincolnshire Y&H Public Health Programmes Team NHS England (North East & Yorkshire).
Finance Manager - Direct Commissioning (HJ & PH), NHS England Regional Team - North East & Yorkshire.
North East and North Cumbria Public Health Commissioning Management Group.
There were no conflicts of Interest.